Blastomycosis Treatment Market Size & Share, by Anatomy (Lung, Bones, Central Nervous System); Treatment {Medication (Itraconazole, Amphotericin B), Surgery}; End-user (Hospital, Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Request Free Sample Copy

Report ID: 3667
Published Date: Mar 31, 2023
Report Format: PDF, PPT

Buy Now

Companies Dominating the Blastomycosis Treatment Landscape

Emcure Pharmaceuticals Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Viatris Inc.
Hindustan Antibiotics Limited
Sun Pharmaceutical Industries Ltd.
Novartis AG
Sanofi-aventis Groupe
Abbott Laboratories
Merck & Co., Inc.
Siemens Healthcare GmbH
Pfizer Inc.

Browse Key Market Insights with Data Illustration:

Blastomycosis Treatment Market Size & Share | Forecast Report 2035

In the News

Viatris Inc. acquired Oyster Point Pharma and Famy Life Sciences, to establish a franchise for ophthalmology.
Sun Pharmaceutical Industries Ltd. obtained US FDA clearance for Amphotericin B injection. Further, Amphotericin B is an antifungal drug used to treat leishmaniasis and severe fungal infections, such as mucormycosis, aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, and cryptococcosis.

Frequently Asked Questions (FAQ)

Growing population of immunocompromised patients and the rising geriatric population are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023-2035.

Diagnoses of blastomycosis can be challenging, and exorbitant cost of treatment are estimated to be the growth hindering factors for the market expansion.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Viatris Inc., Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by treatment, anatomy, end user, and by region.

The medication segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Blastomycosis Treatment Market Size & Share, by Anatomy (Lung, Bones, Central Nervous System); Treatment {Medication (Itraconazole, Amphotericin B), Surgery}; End-user (Hospital, Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Companies Dominating the Blastomycosis Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the blastomycosis treatment market?

What would be the CAGR of blastomycosis treatment market over the forecast period?

What are the challenges affecting the blastomycosis treatment market growth?

Which region will provide more business opportunities for growth of blastomycosis treatment market in future?

Who are the major players dominating the blastomycosis treatment market?

How are the company profiles selected?

What are the segments in the blastomycosis treatment market?

Which segment captures the largest market size in the treatment segment in the blastomycosis treatment market?